Oxaliplatin-related neurotoxicity: is chelation the solution?
Hoff
Paulo M
PM
Gastrointestinal Medical Oncology Department, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA. phoff@mdanderson.org
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002118:Calcium / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000209:etiology*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D002614:Chelating Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D008274:Magnesium; D002118:Calcium